Navigation Links
Phase III Data Show Vanda Pharmaceuticals' Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
Date:6/26/2008

tements

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended March 31, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda'
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, ... a new market research report is ... The Market for Hospital-Acquired Infection Control ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... and healthcare-associated infections (HAIs), demand has ...
(Date:8/20/2014)... 20, 2014 Reportlinker.com announces that ... in its catalogue: Personal Accident ... and Opportunities to 2018 ... report provides in depth market analysis, information ... and health insurance segment, including: - The ...
(Date:8/20/2014)... , Aug. 20, 2014 Torrance ... be using advanced, ventilator technology from Covidien to ... care for patients. The acute ... naturally, compared to conventional mechanical ventilation, and help ... as possible. Patients on mechanical ventilation are often ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2
... Corporation (NASDAQ: DYNT ) today announced results for ... 2011. Sales for the quarter ended December 31, ... the quarter ended December 31, 2010. Sales for the six ... $16,272,232, compared to $16,118,635 for the six months ended December ...
... Company (Nasdaq: PRGO ; TASE) announced that ... tablets, the store brand equivalent to Schering-Plough,s Claritin-D® 12 ... is indicated for the treatment of nasal allergy symptoms. ... to data provided by Wolters, Kluwer. ...
Cached Medicine Technology:Dynatronics Announces Second Quarter Results 2Dynatronics Announces Second Quarter Results 3Dynatronics Announces Second Quarter Results 4Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12 2
(Date:8/21/2014)... York (PRWEB) August 21, 2014 According ... Research "Medical Fiber Optics Market-Global Industry Analysis, Size, Share, ... medical fiber optics market was valued at USD 863.1 ... a CAGR of 7.6% from 2013 to 2019, to ... 2019. , The medical fiber optics market is witnessing ...
(Date:8/21/2014)... The worlds of personal care and yoga ... to grab free products. BaliniSports will be ... Maine with all qualifying purchases for a limited time. ... yoga apparel is simply perfect,” said Ada Hung, founder ... two brands is intended to give people in the ...
(Date:8/21/2014)... 2014 David Mullings’ new book, Things ... powerful collection of quotes from famous entrepreneurs to the ... budding entrepreneurs on their challenging paths towards success. Earth ... inclusion of President and Founder Audrey Darrow alongside the ... self-made celebrities such as Oprah Winfrey, Steve Jobs, and ...
(Date:8/21/2014)... variant of fatty acid-binding protein 4 (FABP4), which ... of heart attack and stroke. The finding revealed ... preventive drug for atherosclerosis. , Led by ... the Department of Neurology at the Hospital District ... atherosclerosis. It is a joint effort involving the ...
(Date:8/21/2014)... researchers at the University of Montreal, the regions of ... as we train our bodies, movements and, critically, they ... researchers knew that sleep helped us the learn sequences ... "The subcortical regions are important in information consolidation, especially ... level is measured after a period of sleep, the ...
Breaking Medicine News(10 mins):Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 2Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 3Health News:Global Medical Fiber Optics Market: Industry Analysis, Size, Share, Growth, Trend and Forecast 2013 - 2019 4Health News:Tom's of Maine Partner up with BaliniSports Yoga Apparel 2Health News:Earth Source Organics President Audrey Darrow Featured in New David Mullings Book 2Health News:A novel pathway for prevention of heart attack and stroke 2Health News:Learning to play the piano? Sleep on it! 2
... say that plastic surgery was performed mainly on Hispanics, Blacks ... this surgery than any other community. It was mainly ... aging. ,Statistics show that more and more people ... million procedures performed. This was a whooping 65 % increase ...
... Tsang said that the public should be responsible and support all ... scare at bay. // ,He asked the public not ... provide timely warnings and emergency tackling plans. ,He said ... said that they should be well prepared to tackle a pandemic. ...
... Kuala Lumpur, Malaysia a two-year-old boy dies at the hospital after ... mouth disease (HFMD). // , This happened in Sarawak ... including the death of the boy. , The child ... hospital. ,Deputy State Chief Minister George Chan said ...
... a 500-capacity British cruise vessel, Funchal that has been around ... the West Australian coast, and will host the medical team, ... been infected by a contagious flu. ,The department's director ... Department of Health is sending a team of specialists to ...
... a Low GI diet, do a rethink. Glycaemic index as a ... ,It is an indicator of sugar in foods. High-GI foods, ... in blood sugar, and some studies have suggested that diets heavy ... disease. ,Still, a direct relation and associations between high-GI foods ...
... of Madhya Pradesh, which has been facing the death of ... has alerted the authorities, who in turn has started investigating ... ,Suraj Damor, the district magistrate of Burhanpur, said 80 ... ,Other reports, however, said some 400 chickens had died ...
Cached Medicine News:Health News:Bird Flu Fear Grips Madhya Pradesh 2
...
Tryptone is the pancreatic digest of casein used as a nitrogen source for bacteria. Ideal for general bacteriological use with a variety of microorganisms. Tryptone is guaranteed BSE-Free....
... 10k units Pen.,10k ug Strept. ... Cell Culture Reagent and Buffer ... with cGMP regulations and are ... compatibility. , Typical Properties, Sterility ...
... (Penicillin G) inhibits bacterial ... synthesis. Streptomycin belongs to ... inhibits bacterial growth by ... is used for prevention ...
Medicine Products: